Expertise in
30
conditions

Dr. Eric N. Bravin

Oncology
Bassett Medical Center
1 Atwell Rd, 
Cooperstown, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
30
conditions
Bassett Medical Center
1 Atwell Rd, 
Cooperstown, NY 

Overview

Eric Bravin is an Oncologist practicing medicine in Cooperstown, New York.

Dr. Bravin is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Angiosarcoma, Lung Adenocarcinoma, Paget Disease of the Breast, Bone Marrow Aspiration, and Gastrostomy.

He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 28 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NY

Hospital Affiliations

Canton-Potsdam Hospital
Southwestern Vermont Medical Center
Bassett Healthcare

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Bassett Medical Center
1 Atwell Rd, Cooperstown, NY 13326

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
View 9 Less Clinical Trials

6 Total Publications

Results of Lung Cancer Screening at a Rural Hospital Network in the United States.
Results of Lung Cancer Screening at a Rural Hospital Network in the United States.
Journal: Journal of community hospital internal medicine perspectives
Published: August 27, 2024
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Amc

47 New Scotland Ave, 
Albany, NY 
 (58.4 miles away)
518-262-5226
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Weaver is an Oncologist practicing medicine in Albany, New York. Dr. Weaver is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Oligodendroglioma, Brain Tumor, Embryonal Tumor with Multilayered Rosettes, and Glioblastoma.

Expertise in
32
conditions
Dr. Heidi E. Godoy
Oncology | Obstetrics and Gynecology
Expertise in
32
conditions
Dr. Heidi E. Godoy
Oncology | Obstetrics and Gynecology
Referral may be required

New York Oncology Hematology PC

400 Patroon Creek Blvd, Ste 211, 
Albany, NY 
 (56.9 miles away)
518-801-0725
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Heidi Godoy is an Oncologist and an Obstetrics and Gynecologist practicing medicine in Albany, New York. Dr. Godoy is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Bladder Reconstruction, and Hernia Surgery. Dr. Godoy is board certified in American Board Of Obstetrics And Gynecology Subspecialty, Gynecologic Oncology and American Board Of Obstetrics & Gynecology, Obstetrics And Gynecology. Dr. Godoy is currently accepting new patients.

Expertise in
18
conditions
Dr. Timothy J. Mcelrath
Oncology | Obstetrics and Gynecology
Expertise in
18
conditions
Dr. Timothy J. Mcelrath
Oncology | Obstetrics and Gynecology
Referral may be required

Womens Cancer Care Assoc LLC

319 S Manning Blvd, Ste 301, 
Albany, NY 
 (56.9 miles away)
518-458-1390
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Timothy Mcelrath is an Oncologist and an Obstetrics and Gynecologist practicing medicine in Albany, New York. Dr. Mcelrath is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Bladder Reconstruction, and Ureteroscopy. Dr. Mcelrath is board certified in American Board Of Obstetrics And Gynecology, American Board Of Obstetrics & Gynecology Subspecialty, Gynecologic Oncology , and American Board Of Obstetrics And Gynecology Subspecialty, Gynecologic Oncology . Dr. Mcelrath is currently accepting new patients.

Frequently Asked Questions about Dr. Eric N. Bravin

How do I make an appointment with Dr. Eric N. Bravin?

You can book an appointment with Dr. Eric N. Bravin by calling their office at 607-547-3336. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Eric N. Bravin a top-rated expert for Angiosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Eric N. Bravin is classified as an Distinguished expert for Angiosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Eric N. Bravin specialize in?

While Dr. Eric N. Bravin is a Oncology, they have specific expertise in Angiosarcoma, Lung Adenocarcinoma, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Eric N. Bravin participate in research or clinical trials?

Yes. Dr. Eric N. Bravin has published 6 articles and abstracts on conditions like Angiosarcoma. You can view a list of Dr. Eric N. Bravin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Eric N. Bravin accept my insurance?

Dr. Eric N. Bravin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 607-547-3336 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bravin's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 23 Advanced Conditions
    View All 83 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile